» Articles » PMID: 2379537

Nonlinear Kinetics of Propafenone Metabolites in Healthy Man

Overview
Specialty Pharmacology
Date 1990 Jan 1
PMID 2379537
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of oral and i.v. propafenone and its major metabolites have been investigated in 8 healthy subjects. The total body clearance of propafenone was 963 ml/min, the terminal half-life 198 min and its absolute bioavailability was 15.5%. The two active metabolites (5-hydroxypropafenone and N-depropylpropafenone) showed non-linear kinetics in that both the dose-corrected area under the serum concentration-time curve and the amount excreted in the urine were larger after oral dosing. This resulted in considerably higher serum concentrations of the metabolites despite comparable serum concentrations of the parent compound. Thus, the concentration-effect relationship in the same patient may differ after oral and intravenous doses if concentrations of the active metabolite(s) are not taken into consideration. Although the mechanism of the nonlinearity is not clear, the data indicate that it may be due to saturable biliary excretion of the metabolites.

Citing Articles

Reduced-dose Antiarrhythmic Drugs: Valuable or Valueless?.

Reiffel J J Innov Card Rhythm Manag. 2020; 11(4):4063-4067.

PMID: 32369043 PMC: 7192146. DOI: 10.19102/icrm.2020.110404.


Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Lu S, Nand R, Yang J, Chen G, Gross A Eur J Clin Pharmacol. 2017; 74(3):285-296.

PMID: 29181698 DOI: 10.1007/s00228-017-2375-3.


Stereoselective steady state disposition and action of propafenone in Chinese subjects.

Li G, Gong P, Qiu J, Zeng F, Klotz U Br J Clin Pharmacol. 1998; 46(5):441-5.

PMID: 9833596 PMC: 1873699. DOI: 10.1046/j.1365-2125.1998.00806.x.


Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Bryson H, Palmer K, Langtry H, Fitton A Drugs. 1993; 45(1):85-130.

PMID: 7680987 DOI: 10.2165/00003495-199345010-00008.


Clinical pharmacokinetics of propafenone.

Hii J, Duff H, Burgess E Clin Pharmacokinet. 1991; 21(1):1-10.

PMID: 1914339 DOI: 10.2165/00003088-199121010-00001.


References
1.
COUMEL P, Leclercq J, Assayag P . European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol. 1984; 54(9):60D-66D. DOI: 10.1016/s0002-9149(84)80288-x. View

2.
DIXON W, MOOD A . The statistical sign test. J Am Stat Assoc. 2010; 41(236):557-66. DOI: 10.1080/01621459.1946.10501898. View

3.
Connolly S, Lebsack C, Winkle R, Harrison D, Kates R . Propafenone disposition kinetics in cardiac arrhythmia. Clin Pharmacol Ther. 1984; 36(2):163-8. DOI: 10.1038/clpt.1984.157. View

4.
Kates R, Yee Y, Winkle R . Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther. 1985; 37(6):610-4. DOI: 10.1038/clpt.1985.97. View

5.
Verbeeck R, Branch R, Wilkinson G . Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet. 1981; 6(5):329-45. DOI: 10.2165/00003088-198106050-00001. View